RPG Life Sciences – Investor Presentation Summary

Key Operational Highlights

  • Flagship brand Naprosyn crossed the milestone of ₹100 crore in secondary sales.
  • The company serves 63+ countries with export relationships and has a reach to over 1 lakh doctors and 3000+ stockists domestically.
  • Manufacturing installed capacity includes 177 crore tablets and 88.5 lakh bottles annually at the Ankleshwar plant, and 12 crore tablets and 3.6 crore capsules annually at the Navi Mumbai plant.
  • Key drivers of operational performance include strong therapy presence in nephrology, rheumatology, oncology, and pain management, along with modernization and capacity expansion initiatives.

Segment-wise Performance

Q2 FY27 Segment Performance (₹ crore):
  • Domestic Formulations: Revenue ₹120.8, Growth 14.8% YoY
  • International Formulations: Revenue ₹43.8, Growth 13.4% YoY
  • API: Revenue ₹41.0, Growth 24.2% YoY (includes ₹0.5 crore from newly acquired Actis Generics business)
H1 FY27 Segment Performance (₹ crore):
  • Domestic Formulations: Revenue ₹233.1, Growth 13.3% YoY
  • International Formulations: Revenue ₹83.8, Growth 9.8% YoY
  • API: Revenue ₹77.3, Growth 18.3% YoY

Explanation of significant changes: Growth in API segment driven by strategic expansion and acquisitions; Domestic Formulations growth supported by strong brand performance.

Financial Highlights

Q2 FY27 Financials (₹ crore):
  • Revenue: ₹205.6
  • EBITDA: ₹34.1 (16.6% margin)
  • Adjusted EBITDA: ₹40.7 (19.8% margin) - excludes one-off restructuring and API acquisition costs of ₹5.5 crore
  • PAT: ₹25.0 (12.2% margin)
  • EPS: Not Specified
H1 FY27 Financials (₹ crore):
  • Revenue: ₹394.2
  • EBITDA: ₹65.8 (16.7% margin)
  • Adjusted EBITDA: ₹71.3 (18.1% margin) - excludes one-off costs of ₹5.5 crore
  • PAT: ₹47.8 (12.1% margin)

YoY comparison: Q2 Revenue up 16.2% YoY; H1 Revenue up 13.8% YoY.

Drivers of financial performance: Higher revenue growth across all business segments and operational efficiencies.

Comparison to market estimates: Not Specified

Key Risks: Not explicitly disclosed

Geographical Revenue Split

Domestic vs Export/Regional Revenue: Not Specified with exact figures

Regional Breakdown: The company exports to 50+ markets across Europe, UK, Canada, Australia, Southeast Asia, Latin America, Africa and other emerging markets.

Balance Sheet Snapshot

Net Debt/Equity: Not Specified

Reserves: Not Specified

Current Assets/Liabilities: Not Specified

Working Capital/Leverage Metrics: Not Specified

Financial Health Insights: Not Specified

Capex & Cash Flow Health

Capital Expenditure: Modernization and capacity expansion in progress at manufacturing facilities, but specific amounts not specified.

Free Cash Flow: Not Specified

Operating Cash Flow: Not Specified

Net Debt Movement: Not Specified

Investment Rationale: Focus on capacity expansion, technology upgrades, and API business scale-up.

Strategic & R&D Initiatives

Investments in Innovation: Digital initiatives including Digital Retina Scanner, Intelligent Chilling Plant Manager, IOT-based AHU monitoring system, Power Management System, e-DMS, e-LMS, and e-QMS platforms.

Expected impact on growth: Not quantitatively specified

Strategic Rationale: Expanding into high-growth markets, reducing operational costs, and building AI-ready leadership through programs like Slingshot.

Industry Trends & Business Environment

Macro/Industry Trends: Not Specified

Impact on Company: Not Specified

Management Commentary & Growth Outlook

Strategic Outlook: The presentation outlines 7 strategic pillars of action for future growth (details not elaborated).

FY Guidance: Not Specified

Market Share Targets: Not Specified

Risks and Opportunities: Not highlighted

Additional Headings

AI Initiatives:
  • RPGserv: AI-enabled digital doctor-support platform for physician engagement
  • GenAI-powered campaign dashboards and RXR 3.0 for salesforce tracking and analytics
  • AI-assisted brand communication and content creation
  • Slingshot AI training programme for leadership team
Happiness Initiatives:
  • Independence Day Celebrations
  • Festival Celebrations
  • Employee Engagement activities
Awards & Recognition:
  • Leading Nephrology Company-2026
  • Excellence in Breakthrough Pharmaceutical Innovations
  • Best Use of AI in Sales Force Effectiveness
  • Best Patent Award
  • Fair Business Practices Award
  • Leading Mid Corporates of India-2025
  • Best Corporate Citizen Award
  • India's Top 500 Value Creators-2023